Lack of effect of intravenous immunoglobulins on tics: A double-blind placebo-controlled study

被引:41
作者
Hoekstra, PJ
Minderaa, RB
Kallenberg, CGM
机构
[1] Child & Adolescent Psychiat Ctr, NL-9713 GZ Groningen, Netherlands
[2] Univ Groningen Hosp, Dept Clin Immunol, Groningen, Netherlands
关键词
D O I
10.4088/jcp.v65n0413
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Case studies and a placebo-controlled study previously suggested the effectiveness of immunomodulatory therapy in patients with tic or related disorders whose symptoms show a relationship with streptococcal infections. No data are available on the effectiveness of intravenous immunoglobulins (IVIG) on tic severity in unselected tic disorder patients. Method: Thirty patients with a DSM-IV tic disorder were randomly assigned to IVIG (1 g/kg on 2 consecutive days: mean age = 28.71 years; range, 14-53 years) or placebo (mean age = 30.73 years; range, 14-63 years). Symptoms were rated with the Yale Global Tic Severity Scale, the Yale-Brown Obsessive Compulsive Scale, and the Clinical Global Impressions scale of symptom change with regard to tic severity. These were used at baseline and on weeks 2, 4, 6, 10, and 14 posttreatment, after which blinding was broken. The study was conducted from March through August 2002. Results: We observed no significant differences between both treatment groups regarding posttreatment changes in tic severity. Severity of obsessions and compulsions, which was in the subclinical range, decreased significantly in the IVIG group compared with the placebo group at week 6 (p = .02). Then, there was a 32.3% improvement in the IVIG group compared with baseline. Though this improvement was maintained over the following 8 weeks, no statistically significant differences between the IVIG and the placebo group with regard to improvements in obsessions and compulsions were detected at subsequent assessments. IVIG treatment was associated with significantly more side effects than placebo, most notably headache. Conclusion: Based on the present results, IVIG cannot be recommended in tic disorders.
引用
收藏
页码:537 / 542
页数:6
相关论文
共 28 条
[1]   CASE-STUDY - A NEW INFECTION-TRIGGERED, AUTOIMMUNE SUBTYPE OF PEDIATRIC OCD AND TOURETTES-SYNDROME [J].
ALLEN, AJ ;
LEONARD, HL ;
SWEDO, SE .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1995, 34 (03) :307-311
[2]   The course and prognosis of Tourette syndrome [J].
Bruun, RD ;
Budman, CL .
NEUROLOGIC CLINICS, 1997, 15 (02) :291-+
[3]   Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis [J].
Church, AJ ;
Dale, RC ;
Lees, AJ ;
Giovannoni, G ;
Robertson, MM .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (05) :602-607
[4]   The course of Tourette's disorder: A literature review [J].
Coffey, BJ ;
Biederman, J ;
Geller, DA ;
Spencer, T ;
Park, KS ;
Shapiro, SJ ;
Garfield, SB .
HARVARD REVIEW OF PSYCHIATRY, 2000, 8 (04) :192-198
[5]  
FAHN S, 1993, ARCH NEUROL-CHICAGO, V50, P1013
[6]   CORTICOSTEROID-THERAPY AND TOURETTE SYNDROME [J].
GESCHWIND, N .
ANNALS OF NEUROLOGY, 1979, 5 (05) :495-495
[7]  
GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006
[8]  
GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1012
[9]  
Guy W., 1976, ECDEU ASSESSMENT PSY, P217
[10]   Is Tourette's syndrome an autoimmune disease? [J].
Hoekstra, PJ ;
Kallenberg, CGM ;
Korf, J ;
Minderaa, RB .
MOLECULAR PSYCHIATRY, 2002, 7 (05) :437-445